Itochu stock loses 1.06 percent after-hours to EUR 12.18
Published on 10/07/2026 at 20:31 | Editorial responsibility: Rafael MĂŒller, Editor-in-Chief AD HOC NEWS
Lang & Schwarz quoted Itochu at EUR 12.18 after-hours at 8:28 p.m. CEST on October 7, 2026, down 1.06 percent versus the prior close of EUR 12.31 on October 6, 2026. The bid was EUR 12.12 and the ask was EUR 12.25. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Itochu stock.
Healthcare and AI development
On October 7, 2026, ITOCHU Corporation said it had signed a capital alliance agreement with MOLCURE Inc., which has AI-driven drug discovery technologies for antibodies and peptides. The companies aim to combine MOLCUREâs technology with ITOCHU Group pharmaceutical development support functions and domestic and international business networks. The planned support system is intended to cover the creation of drug candidates through AI-driven discovery as well as preclinical and clinical development.
MOLCUREâs platform includes a proprietary large language model, physical simulation technologies and experimental data from its biological laboratory. The company focuses on designing and optimizing antibody candidates and other molecules for pharmaceutical companies and research institutions in Japan and overseas. ITOCHU said its healthcare and life sciences activities already include support for the research and development process through A2 Healthcare Corporation, a wholly owned subsidiary involved in clinical development across multiple therapeutic areas. The release identified MOLCUREâs capital at JPY 10 million and said it was established in 2013.
